Dermatomyositis Market Size (7MM) was ~USD 187 million in 2023, It is expected to grow at a CAGR of 16.8% by 2034, estimates DelveInsight

DelveInsight's "Dermatomyositis Market Insight, Epidemiology, and Market Forecast - 2034" provides an in-depth analysis of the current landscape and future outlook of the Dermatomyositis market across major geographies, including the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. The report explores detailed epidemiological trends, segmentation by age and clinical subtypes, and diagnostic challenges that contribute to underreporting and delayed intervention.

Discover Key Insights into the Dermatomyositis Market with DelveInsight's In-Depth Report @ Dermatomyositis Market Size @ https://www.delveinsight.com/sample-request/dermatomyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Dermatomyositis Market Report
• The total diagnosed Dermatomyositis prevalence in the United States were around 38.5 thousand cases in 2023.
• The United States contributed to the largest diagnosed prevalent population of Dermatomyositis, acquiring ~54% of the 7MM in 2023. Whereas, EU4 and the UK, and Japan accounted for around 29% and 17% of the total population share, respectively, in 2023.
• Among the EU4 countries, Germany accounted for the largest number of diagnosed prevalent Dermatomyositis (5,272 Cases) cases followed by the UK (4,594 Cases), whereas Spain accounted for the lowest number of cases (3,053 Cases) in 2023.
• In 2023, it was estimated that there were around 15 thousand diagnosed cases in the age group of 40-59, followed by 13 thousand in 60-79 age group, 5,400 cases in 18-39 age group, 4,200 cases in 0-17 age group, and 1200 cases in 80 years and older in the US.
• According to DelveInsight estimates, in 2023 there were approximately 6,937 diagnosed prevalent cases of Mild type and about 5,476 cases of Moderate to severe type in Japan.
• In 2023, Dermatomyositis affected ~12 thousand males and ~26 thousand females in the United States.
• In 2023, DelveInsight analysis of the chronicity-specific data in the US revealed that 70% of people affected with Dermatomyositis have Chronic type, while 30% have the Acute Type.
• In Japan in 2023, comorbidity-specific cases accounted for the following percentages of diagnosed prevalent cases: ILD at 20%, CVD at 18%, cancer malignancy at 4%, and other conditions (including osteoporosis, dysphagia, Raynaud's syndrome, calcinosis, etc.) at 58%.
• The leading Dermatomyositis Companies such as Kezar Life Sciences, Argenx, Pfizer, CSL Behring, Viela Bio, PAEAN Biotechnology, Alexion Pharmaceuticals, and others.
• Promising Dermatomyositis Therapies such as KZR-616, EFG PH20, PF 06823859, Hizentra, Daxdilimab, PN 101, Ravulizumab, and others.

To know in detail about the Dermatomyositis market outlook, drug uptake, treatment scenario, and epidemiology trends, click here @ Dermatomyositis Market Forecast- https://www.delveinsight.com/sample-request/dermatomyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Dermatomyositis Overview
Dermatomyositis is a rare, systemic autoimmune disorder characterized by chronic inflammation of the skin and muscles. It presents with hallmark features such as symmetric proximal muscle weakness and distinctive skin rashes, including the heliotrope rash and Gottron's papules. The condition may also affect other organs, including the lungs, esophagus, and heart, and is sometimes associated with malignancy, especially in adults. Dermatomyositis affects both adults and children (juvenile Dermatomyositis), with varying severity. Its exact etiology remains unclear but is believed to involve a combination of genetic predisposition, immune system dysregulation, and environmental triggers. Diagnosis typically involves a combination of clinical findings, elevated muscle enzymes, electromyography (EMG), imaging studies, skin/muscle biopsies, and autoantibody testing. Management of Dermatomyositis requires a multidisciplinary approach, involving dermatologists, rheumatologists, neurologists, and physical therapists. While there is no cure, a range of therapies aim to control inflammation, alleviate symptoms, and prevent complications.

Dermatomyositis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
• Diagnosed Dermatomyositis prevalence
• Type-specific Diagnosed Dermatomyositis prevalence
• Age-specific Diagnosed Dermatomyositis prevalence
• Gender-specific Diagnosed Prevalent Cases of Dermatomyositis
• Severity-specific Diagnosed Prevalent Cases of Dermatomyositis
• Chronicity-specific Diagnosed Prevalent Cases of Dermatomyositis

Download the report to understand which factors are driving Dermatomyositis epidemiology trends @ Dermatomyositis Epidemiology Forecast- https://www.delveinsight.com/sample-request/dermatomyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Dermatomyositis Marketed Drugs
• OCTAGAM 10% (immunoglobulin): Octapharma
OCTAGAM 10% (immune globulin intravenous [human]) is the first and only intravenous immunoglobulin (IVIg) product indicated for the treatment of primary humoral immunodeficiency, chronic Immune Thrombocytopenic Purpura (ITP) and dermatomyositis. IVIG replacement therapy is the apparent treatment of choice for humoral primary immunodeficiency, such as dermatomyositis, as these patients cannot mount an effective immune response toward pathogens. Additionally, IVIg acts as a corticosteroid-sparing agent and represents a unique dermatomyositis treatment options for patients. They are safe and effective treatment options, especially in patients showing no response or incomplete response to corticosteroids or who experience severe side effects. It is made from healthy human blood with a high level of certain defensive substances (antibodies), which help fight infections, and is also used to increase the blood count (platelets) in persons with a certain blood disorder, ITP.

Dermatomyositis Emerging Drugs
• Brepocitinib: Priovant Therapeutics/Pfizer
Brepocitinib, being developed by Priovant Therapeutics, is an oral, once-daily dual inhibitor of TYK2 and JAK1. It targets the cytokine signaling pathways implicated in autoimmune diseases, including Type I and Type II interferon, IL-6, IL-12, and IL-23. This dual inhibition is intended to provide a broad suppression of these pathways, which are involved in the pathogenesis of dermatomyositis. Brepocitinib has shown promising results in several Phase II studies, demonstrating its efficacy and safety. Currently, it is being evaluated in a registrational Phase III trial specifically for dermatomyositis, aiming to address the significant unmet need for effective and convenient treatments for this condition.

• Efgartigimod: Argenx
Efgartigimod is an SC product combination of efgartigimod alfa and recombinant human hyaluronidase PH20 (rHuPH20). Efgartigimod targets the neonatal Fc receptor (FcRn) as a first-in-class investigational antibody fragment. Efgartigimod binds to the neonatal Fc receptor and inhibits its interaction with IgG, thereby reducing IgG recycling and increasing the degradation of IgG and pathological auto-antibodies without altering other immunoglobulins and albumin levels. It is undergoing a Phase III and II/III dermatomyositis clinical trials in participants with active IIM subtypes, including dermatomyositis. Further, the interim analysis of the first 30 patients of each subset is expected by 2024.

Dermatomyositis Drugs Uptake and Pipeline Development Activities
The Dermatomyositis drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being adopted in the Dermatomyositis market during the study period. This analysis covers drug uptake, patient adoption of therapies, and the sales performance of each drug. Additionally, the therapeutics assessment section highlights the drugs with the most rapid uptake, shedding light on the factors driving their widespread use. It also provides a comparative analysis of these drugs based on their market share. The report further delves into the Dermatomyositis pipeline development activities, offering key insights into various therapeutic candidates in different stages of development and the major companies behind these innovations. It also covers recent collaborations, acquisitions, mergers, licensing agreements, patent details, and other critical information related to emerging therapies.

Dermatomyositis Market Outlook
There is no cure for Dermatomyositis; however, medication can reduce inflammation and vasculitis, invariably minimize symptomatology, and improve the patient's quality of life. The recent approval of OCTAGAM and the presence of several management guidelines, including the British Society for Rheumatology guideline, the Japanese Society of Rheumatology guideline, and others, have revolutionized the treatment landscape of dermatomyositis. Several other off-label medications, including corticosteroids, immunosuppressants, antimalarial drugs, antibiotics, and topical ointments, are used individually or in combination to eliminate symptoms.

Dermatomyositis Market Strengths
• A strong research focus on immune pathways (e.g., JAK-STAT, interferon) has led to promising investigational drugs such as Brepocitinib and Anifrolumab, indicating future therapeutic breakthroughs.
• Increasing awareness among clinicians and availability of diagnostic tools (e.g., autoantibody profiling, MRI) enable earlier diagnosis and more tailored treatment strategies.

Dermatomyositis Market Weaknesses
• Despite multiple treatment options, none offer a cure, and many patients experience relapses or partial responses, necessitating lifelong management.
• A significant portion of treatment regimens relies on off-label drug use, which lacks robust clinical trial data, leading to variable efficacy and safety outcomes across patient populations.

Learn more about the FDA-approved drugs for Dermatomyositis @ Drugs for Dermatomyositis Treatment- https://www.delveinsight.com/sample-request/dermatomyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Dermatomyositis Market Report
• Study Period: 2020-2034
• Coverage: 7MM
• Dermatomyositis Companies: Kezar Life Sciences, Argenx, Pfizer, CSL Behring, Viela Bio, PAEAN Biotechnology, Alexion Pharmaceuticals, and others.
• Dermatomyositis Therapies: KZR-616, EFG PH20, PF 06823859, Hizentra, Daxdilimab, PN 101, Ravulizumab, and others.
• Dermatomyositis Therapeutic Assessment: Dermatomyositis, currently marketed, and Dermatomyositis emerging therapies
• Dermatomyositis Market Dynamics: Dermatomyositis market drivers and Dermatomyositis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Dermatomyositis Unmet Needs, KOL's views, Analyst's views, Dermatomyositis Market Access and Reimbursement

To learn more about the key players and advancements in the Dermatomyositis treatment landscape, visit the Dermatomyositis Market Analysis Report @ https://www.delveinsight.com/sample-request/dermatomyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Dermatomyositis Market Report Introduction
2. Executive Summary for Dermatomyositis
3. SWOT analysis of Dermatomyositis
4. Dermatomyositis Patient Share (%) Overview at a Glance
5. Dermatomyositis Market Overview at a Glance
6. Dermatomyositis Disease Background and Overview
7. Dermatomyositis Epidemiology and Patient Population
8. Country-Specific Patient Population of Dermatomyositis
9. Dermatomyositis Current Treatment and Medical Practices
10. Dermatomyositis Unmet Needs
11. Dermatomyositis Emerging Therapies
12. Dermatomyositis Market Outlook
13. Country-Wise Dermatomyositis Market Analysis (2020-2034)
14. Dermatomyositis Market Access and Reimbursement of Therapies
15. Dermatomyositis Market Drivers
16. Dermatomyositis Market Barriers
17. Dermatomyositis Appendix
18. Dermatomyositis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.